Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by inthnoon Feb 02, 2023 8:54am
257 Views
Post# 35261797

RE:SHORT INTEREST - VERY SMALL IF ANY

RE:SHORT INTEREST - VERY SMALL IF ANYIf the number of oustanding shares is correct at 61,330,000 then that is an increase of over 2 million shares as shown from the last corporate presentation.which shows the company is still activley using the ATM which is a necessity one would think,


Financial data as of Sep. 30, 2022, Share Count data as of Nov. 3, 2022, and Market Cap. data as of Jan. 19, 2023
Exchanges Nasdaq: ONCY / TSX: ONC
Market Cap. Approx. $113M
Cash & Equivalents CDN $32.4M (USD $24M)
Based on FX as of Nov. 8, 2022
Shares Outstanding 59,028,688
Fully Diluted 64,388,508
<< Previous
Bullboard Posts
Next >>